Key Milestones and Financial Results of CorMedix (CRMD) in Q4 2023 Earnings Call
Tuesday, 12 March 2024, 20:15
CorMedix (CRMD) Q4 2023 Earnings Call Highlights
CorMedix (CRMD) reported achieving key milestones including final NDA approval and TDAPA eligibility for DefenCath. The company is on track for a commercial launch in 2024 and anticipates break-even profitability by December 2024.
Financial Results
- Increased net loss in Q4 2023 primarily due to higher expenses related to market studies and personnel costs.
- Total operating expenses for full year 2023 increased to $49 million with R&D expenses driven by personnel and medical affairs activities.
- Net cash used in operations in 2023 was $38.4 million, primarily due to operating expenses.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.